"We are still in our early years of building market share infrastructure with a strong and disciplined sales organization so we will necessarily take advantage of certain investment opportunities that will move our operating profit and Adjusted EPS* around somewhat. However, that should not be disconcerting to our shareholders. We continue to build a strong asset base at MiMedx related to patents and other intellectual property, new product developments, reimbursement and management and executive talent. We have become one of the most respected regenerative medicine companies in advanced wound care, and we believe we will quickly build the same reputation in certain sectors of the surgical area," noted Petit.